The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...

Maxim Group analyst Jason McCarthy has maintained their bullish stance on RZLT stock, giving a Buy rating yesterday. Jason McCarthy has given ...

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

Sunir J. Garg, MD, reflects on the recent American Academy of Ophthalmology meeting in Chicago and shares key insights on managing diabetic macular edema (DME). Dr Garg highlights new data showing ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital, dedicated to the development and ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

New Delhi: The drug major Sun Pharmaceutical Industries has got approval from the Subject Expert Committee (SEC) functional ...

Watertown-based EyePoint Pharmaceuticals is scheduled this week to formally open its new 40,000-square-foot manufacturing ...